Pneumococcal vaccine for adults and at risk groups (2025)
UK Health Security Agency · awarded 18 December 2024
£1
Award value
£1
1
Supplier
Recorded as a large business
30 Apr 2029
Runs until
from 1 May 2025
Who
| Buyer | UK Health Security Agency London |
|---|---|
| Supplier |
Pfizer Ltd |
| Category | goods |
| Classification | Vaccines CPV 33651600 |
| Notice published | 20 December 2024 |
What it is for
A contract for the supply of pneumococcal vaccine for adults and at risk groups (2025). Deliveries will be required over a period of 2 years, with an option to extend for up to an additional 24 months. Value - The contract value is withheld from publication pursuant to regulation 50(6)(b) of the Public Contracts Regulations 2015 (as amended) so as not to prejudice the legitimate commercial interest of the supplier.
Read the original award notice on Contracts Finder →
Other contracts from this buyer
540 awards on file, worth £872.1m.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 1 Jun 2026 | Live Attenuated Influenza vaccine 2026/2027 | UK Health Security Agency | ASTRAZENECA UK LIMITED | £225.4m |
| 18 Jan 2022 | Single Service Centre - HGS | UK Health Security Agency | HINDUJA GLOBAL SOLUTIONS UK LIMITED | £211.9m |
| 3 Dec 2025 | Select Item 1 UKHSA Trust Programme Delivery Partner | UK Health Security Agency | PA CONSULTING SERVICES LIMITED | £29.6m |
| 18 Sep 2024 | Enterprise Data Platform Delivery partner | UK Health Security Agency | KAINOS SOFTWARE LIMITED | £18.0m |
| 18 Sep 2024 | Enterprise Data Platform Delivery partner | UK Health Security Agency | KAINOS SOFTWARE LIMITED | £18.0m |
Everything UK Health Security Agency has awarded →
Other contracts won by this supplier
11 awards on file, worth £3.6bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
| 22 Jul 2024 | NHS Branded Medicines Tranche Framework for London and South of EnglandEast Midlands | NHS England | Sun Pharma UK Ltd +28 | £381.0m |
| 25 Jun 2025 | NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National | NHS England | Roche Products Ltd +27 | £261.9m |